Who Owns Standard BioTools Company?

Who Owns Standard BioTools?

Understanding Standard BioTools' ownership is key to its strategic path. The acquisition of SomaLogic in January 2024 for over $1 billion in an all-stock deal significantly altered its ownership structure, aiming to create a multi-omics leader.

The company, originally founded in 1999, has evolved through rebranding and strategic mergers, now serving the life science research market with advanced tools.

Standard BioTools Inc. develops instruments and software for single-cell biology and proteomics. Their offerings, like those analyzed in the Standard BioTools BCG Matrix, support drug discovery and personalized medicine. As of November 2024, the company's market capitalization stood at $435.83 million.

Standard BioTools Inc. began its journey in 1999, initially established as Mycometrix by its founders, Dr. Stephen Quake and Dr. Gajus Worthington. Dr. Worthington took on the role of chief executive officer from the company's inception until 2016, while Dr. Quake has continued his involvement as a member of the scientific advisory board.

Founding Year

Standard BioTools was founded in 1999, marking the beginning of its operations in the life sciences sector.

Founders

The company was established by Dr. Stephen Quake and Dr. Gajus Worthington.

Early Leadership

Dr. Gajus Worthington served as CEO from 1999 to 2016, guiding the company through its formative years.

Initial Funding

The company secured approximately $4.5 million in seed funding to fuel its early research and development initiatives.

Key Hire

Richard DeLateur, with two decades of experience at Intel, joined in 2006 as the chief financial officer.

Technological Focus

The company's initial efforts centered on commercializing microfluidic large-scale integration technology.

The company's early strategic direction involved the development of integrated fluidic circuits (IFCs), a testament to its focus on microfluidic advancements. By 2009, the company had garnered recognition as a leading manufacturer in the microfluidic devices sector, underscoring its progress in this specialized field. This period laid the groundwork for its future innovations and market presence, a journey detailed further in the Brief History of Standard BioTools.

Early Company Milestones

The initial years of Standard BioTools were characterized by foundational development and strategic growth.

• Founded in 1999 as Mycometrix.
• Led by founders Dr. Stephen Quake and Dr. Gajus Worthington.
• Received approximately $4.5 million in seed funding.
• Focused on commercializing microfluidic large-scale integration technology.
• Recognized as a leading microfluidic device manufacturer by 2009.

Complete Standard BioTools Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The ownership structure of Standard BioTools Inc. has seen significant evolution, notably with a major strategic investment and a subsequent merger that reshaped its stakeholder landscape. These events have been pivotal in defining the company's current corporate identity and strategic direction.

Following a substantial $250 million investment in April 2022 by Casdin Capital, LLC and Viking Global Investors LP, Fluidigm Corporation was rebranded as Standard BioTools Inc., signaling a strategic pivot. This move underscored a commitment to becoming a more diversified and innovation-focused life science tools company, particularly targeting the pharmaceutical research markets. As of December 31, 2024, the company had 377,529,825 shares of Common Stock outstanding. Institutional investors represent a significant portion of the Standard BioTools ownership, holding 74.18% of shares as of April 2025, a figure consistent with March 2025. Key institutional shareholders as of July 2025 include Casdin Capital, LLC, Viking Global Investors LP, BlackRock, Inc., Vanguard Group Inc, and Morgan Stanley, among other large funds. Casdin Capital and Viking Global Investors LP were instrumental in the April 2022 capital infusion.

Key Stakeholders in Standard BioTools

Major institutional investors hold a commanding majority of Standard BioTools' shares, reflecting significant confidence in the company's strategic direction and future growth prospects.

• Casdin Capital, LLC
• Viking Global Investors LP
• BlackRock, Inc.
• Vanguard Group Inc
• Morgan Stanley

A transformative event in the company's history was the all-stock merger with SomaLogic, finalized in January 2024. This acquisition saw SomaLogic shareholders exchange their shares for 1.11 shares of Standard BioTools common stock per SomaLogic share. Post-merger, Standard BioTools shareholders held approximately 43% of the combined entity, while SomaLogic shareholders owned about 57% on a fully diluted basis. The combined company reported pro-forma revenues exceeding $180 million for the full year 2023 and approximately $175.1 million for the full year 2024. The merger is projected to achieve estimated annual cost synergies of $80 million by 2026, a key element of the Marketing Strategy of Standard BioTools.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors for Standard BioTools Inc. currently consists of seven members, a structure established after its merger with SomaLogic. This board includes three directors appointed by Standard BioTools: Michael Egholm, Fenel Eloi, and Frank Witney. SomaLogic designated three directors: Tom Carey, who also chairs the board, Troy Cox, and Kathy Hibbs. Eli Casdin remains a member of the combined company's board. Michael Egholm holds the positions of President and Chief Executive Officer.

The voting power within Standard BioTools Inc. is primarily structured on a one-share-one-vote basis for holders of its Common Stock. As of December 31, 2024, the company had 377,529,825 shares of Common Stock outstanding. Additionally, Series B Preferred Stock shares carry voting rights, calculated according to their respective Certificates of Designations, and vote alongside the common stock. At the 2025 Annual Meeting, approximately 86.06% of the 379,822,268 total outstanding shares were represented. Certain significant corporate actions, such as amendments to the company's charter, require approval from a majority of the board and at least 66 2/3% of the total voting power of all outstanding voting securities, cast as a single class.

Board and Shareholder Influence

The composition of the board reflects the recent merger, with representation from both former entities. Shareholder voting power is concentrated in the common stock, with specific provisions for preferred stock. Understanding the Growth Strategy of Standard BioTools is crucial for evaluating the board's decisions and their impact on shareholder value.

• Board composition reflects merger integration.
• Common stock holds primary voting power.
• Preferred stock has voting rights based on designations.
• Supermajority vote required for charter amendments.

Standard BioTools Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Standard BioTools Inc. has experienced significant ownership changes, notably its merger with SomaLogic, which concluded in early 2024. This strategic move reshaped the company's shareholder structure, with SomaLogic stakeholders now holding a majority. The company continues to focus on its life sciences tools mission, supported by substantial capital investments and a growing institutional investor base.

Institutional investors are a dominant force in Standard BioTools' ownership landscape. As of July 25, 2025, these entities collectively held over 313 million shares. This significant institutional backing, coupled with a slight increase in insider and mutual fund holdings observed in April 2025, indicates a stable yet evolving shareholder profile. The company is strategically positioning itself for financial growth, targeting adjusted EBITDA positivity by 2026 through a focus on high-margin products and collaborations, as detailed in their Revenue Streams & Business Model of Standard BioTools.

Institutional Investor Dominance

As of July 25, 2025, institutional investors held 313,100,254 shares. This substantial stake underscores the confidence of large investment firms in the company's future.

Merger Impact on Ownership

The January 2024 merger with SomaLogic resulted in a new ownership structure. SomaLogic shareholders now comprise approximately 57% of the combined entity.

Strategic Financial Infusion

In April 2022, a $250 million capital infusion from prominent investors marked a turning point. This funding supported the company's rebranding and strategic acceleration.

Ownership Trend Stability

Institutional ownership remained steady at 74.18% as of April 2025. Insider holdings saw a minor increase, reflecting continued management commitment.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE